Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/172324
Title: | Remote control of movement disorders using a photoactive adenosine A(2A) receptor antagonist |
Author: | Taura, Jaume Nolen, Ernest G. Cabre, Gisela Hernando, Jordi Squarcialupi, Lucia López-Cano, Marc Jacobson, Kenneth A. Fernández Dueñas, Víctor Ciruela Alférez, Francisco |
Keywords: | Malaltia de Parkinson Adenosina Parkinson's disease Adenosine |
Issue Date: | 10-Aug-2018 |
Publisher: | Elsevier Science |
Abstract: | G protein-coupled adenosine receptors are promising therapeutic targets for a wide range of neuropathological conditions, including Parkinson's disease (PD). However, the ubiquity of adenosine receptors and the ultimate lack of selectivity of certain adenosine-based drugs have frequently diminished their therapeutic use. Photopharmacology is a novel approach that allows the spatiotemporal control of receptor function, thus circumventing some of these limitations. Here, we aimed to develop a light-sensitive caged adenosine A(2A) receptor (A(2A)R) antagonist to photocontrol movement disorders. We synthesized MRS7145 by blocking with coumarin the 5-amino position of the selective A(2A)R antagonist SCH442416, which could be photoreleased upon violet light illumination (405 nm). First, the light-dependent pharmacological profile of MRS7145 was determined in A(2A)R-expressing cells. Upon photoactivation, MRS7145 precluded A(2A)R ligand binding and agonist-induced cAMP accumulation. Next, the ability of MRS7145 to block A(2A)R in a light-dependent manner was assessed in vivo. To this end, A(2A)R antagonist-mediated locomotor activity potentiation was evaluated in brain (striatum) fiber-optic implanted mice. Upon irradiation (405 nm) of the dorsal striatum, MRS7145 induced significant hyperlocomotion and counteracted haloperidol-induced catalepsy and pilocarpine-induced tremor. Finally, its efficacy in reversing motor impairment was evaluated in a PD animal model, namely the hemiparkinsonian 6-hydroxydopamine (6-OHDA)-lesioned mouse. Photo-activated MRS7145 was able to potentiate the number of contralateral rotations induced by L-3,4-dihydroxyphenylalanine (L-DOPA). Overall, MRS7145 is a new light-operated A(2A)R antagonist with potential utility to manage movement disorders, including PD. |
Note: | Reproducció del document publicat a: https://doi.org/10.1016/j.jconrel.2018.05.033 |
It is part of: | Journal of Controlled Release, 2018, vol. 283, p. 135-142 |
URI: | http://hdl.handle.net/2445/172324 |
Related resource: | https://doi.org/10.1016/j.jconrel.2018.05.033 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
TauraJ.pdf | 1.64 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License